Since about mid-2015, or over nine years, we’ve been covering the immuno-oncology battles of major pharma concerns. Specifically, we offered deep coverage of the patent fights (Cabilly I, II and III patent fights) between Merck and Roche. [Hint: just search “Roche” in the box, at upper right.]
But it seems those will fade in importance, now that Merck is posting wins in progression free survival — over Tecentriq, at least in some non-squamous lung cancers, in head to head comparisons. [So too, with the other main competitor, Optivo, from BMS.] Here’s that report — and a bit:
…On Thursday, Roche Holdings AG said that the Phase 2/3 SKYSCRAPER-06 study of tiragolumab plus Tecentriq (atezolizumab) and chemotherapy
versus pembrolizumab and chemotherapy as first-line treatment for locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, did not meet its primary endpoints of progression-free survival (PFS) at its primary analysis….
Now you know — and it looks like the side-effect profile for pembrolizumab is milder than the Roche offering. So, as we’ve long predicted, it seems Merck has clear sailing into the 2030s now.
Onward, grinning… bike riding time.
नमस्ते
Powerline Lies... 